Drug intelligence / Profile preview

alloxan

Development stage
Discontinued
Modality
Small Molecules
Administration
Intraperitoneal, Intravenous (experimental)
01

Overview

Alloxan is a small organic molecule (C4H2N2O4) classified as a pyrimidone derivative. It is historically notable as one of the earliest organic compounds discovered and has wide utility in biomedical research as a selective toxin for pancreatic beta cells. Alloxan induces insulin-dependent diabetes mellitus in laboratory animals by generating reactive oxygen species (ROS) within beta cells, predominantly via redox cycling with dialuric acid and interactions with intracellular thiols like glutathione. Through its selective accumulation in beta cells (via the GLUT2 glucose transporter), it inhibits glucokinase—the beta cell glucose sensor—blocking glucose-induced insulin secretion and ultimately causing beta cell necrosis. Alloxan has also been used experimentally in homeopathic medicine, though it is not used therapeutically in conventional medicine.

Other names
2,4,5,6(1H,3H)-pyrimidinetetronemesoxalylureamesoxalylcarbamidealloxan monohydrate
02

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on alloxan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alloxan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call